secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001104659-23-060813
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics updates pipeline timelines; cash $123M, runway into 2H2024
----------------------------------------------------------------------------

- KORSUVA injection US launch ongoing; Japan approval expected 2H2023; EU launch 2H2022.
- Oral difelikefalin Phase 3 for non-dialysis CKD-aP (KICK1/2) topline data 2H2024.
- Phase 3 for atopic dermatitis (KIND1/2) internal readout 4Q2023, topline 1H2025.
- Phase 2/3 for notalgia paresthetica (KOURAGE1) internal readout 2H2024.
- Cash $123M as of Mar 31, 2023; no debt; cash runway into 2H2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923060813/0001104659-23-060813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923060813/tm2315680d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-060813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer